Innlegg
Happy_shanky
🚨 $LLY — ELI LILLY’S NEXT OBESITY DRUG SHOWS STRONG RESULTS
ELI LILLY’S EXPERIMENTAL ELORALINTIDE, WHEN COMBINED WITH ZEPBOUND, PRODUCED AN AVERAGE 23.3% WEIGHT LOSS OVER AROUND 11 MONTHS.
THAT COMPARES WITH 14.8% FOR ZEPBOUND ALONE IN PATIENTS WITH TYPE 2 DIABETES.
⚠️ HOWEVER, 11%–27% OF PATIENTS STOPPED THE COMBINATION DUE TO SIDE EFFECTS, KEEPING TOLERABILITY AS AN IMPORTANT CONSIDERATION.
LILLY EXPECTS TO MOVE ELORALINTIDE INTO LATE-STAGE TRIALS LATER THIS YEAR.
#DailyOrbit
Ansvarsfraskrivelse: OKX Orbit-innholdet er kun gitt for informasjonsformål. Finn ut mer
Svar
Ingen kommentarer ennå. Vær den første til å svare!
